A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

Inclusion Criteria: * The age is 18-70 years old. * The written informed consent of the patient / legal representative is obtained before any program related implementation. * Metastatic or non resectable, locally advanced gastric or gastroesophageal adenocarcinoma, confirmed by histology or cytology. * The development of objective imaging after first-line chemotherapy (RECIST1.1); * There were measurable lesions (according to RECIST1.1); * Can provide tumor tissue specimens; * PDL1 positive (only for the second, third stage) or MSI test positive; * Time interval to last chemotherapy is at least 1 month. * 0-1 ECOG score * The expected survival time is more than 4 months * Peripheral blood cell culture showes the proliferation of lymphocytes Exclusion Criteria: * Participate in the plan or implementation of the research (including staff of HRYZ and the staff of the research center); * Participate into other clinical studies at the same time, unless it is an observational (non - intervention) clinical study; * Subjects may receive other systemic antitumor treatment during the study. * Squamous or undifferentiated gastric cancer * There were active bleeding, ulcers, gastrointestinal perforation, fistula, or arterial embolism in the gastrointestinal tract within 6 months. * There were clinically significant gastrointestinal bleeding or venous thrombosis in three months before enrollment. * End-stage cachexia patients; * Patients with severe coagulation dysfunction; * Patients with extensive abdominal adhesions; * Patients with intestinal obstruction; * Pregnancy or planned pregnancy; * Refusing to provide blood specimens; * Hypersensitivity to sodium citrate; * Subjects have received allogeneic transplantation * Subjects had clinical symptoms of central nervous system metastasis (such as brain edema, requiring hormone intervention, or progression of brain metastases) * Subjects are using immunosuppressive agents, or whole body or absorbable local hormone therapy to achieve the aim of immunosuppression (dose \>10mg/ days prednisone or other therapeutic hormones) and continue to use in the first 2 weeks before enrollment. * Systemic or long-term application of immunomodulators, such as interferon, thymosin, and immunosuppressive drugs, in half a year. * Subjects had been treated with MASCT or other cellular immunotherapy within a year. * Subjects had any active autoimmune disease or a history of autoimmune disease. * Active tuberculosis * There is a big operation in 30 days before the first study treatment. * Patients with active hepatitis B virus (HBV) infection (chronic or acute) * The infection of active hepatitis C virus (HCV) * Suffering from human immunodeficiency virus (HIV) or syphilis * A history of peripheral nervous system disorder or a history of obvious mental disorders and central nervous system disorders * Subjects had active infection or \>38.5 degree of unexplained fever in the screening period and before the first administration. * Chronic systemic diseases, such as liver disease (such as cirrhosis, etc.), kidney disease, respiratory disease, or non controlled diabetes, hypertension, etc. * There were other malignant tumors in 5 years, except for non melanin skin cancer and cervical carcinoma in situ * There are heart symptoms or diseases that have not been well controlled. * Subjects were known to have a history of psychotropic drug abuse, alcoholism, or drug abuse. * According to the researchers, there are other factors that may lead to a halt.